11/11/2020 4:04:14 PM
Xencor, MorphoSys And Incyte Announce Clinical Collaboration For
Tafasitamab In Combination With Plamotamab
11/5/2020 7:17:24 AM
Incyte Q3 GAAP Loss Per Share $0.07; Non-GAAP EPS $0.23
10/31/2020 11:25:51 AM
LLY: Phase 3 Study Results Shows Baricitinib' Efficacy At Achieving Clear Or Almost Clear Skin Could Be Sustained
10/30/2020 6:51:41 AM
Lilly And Incyte To Present Positive New Data For Baricitinib In Adult Patients With Alopecia Areata
10/29/2020 8:12:56 AM
Incyte Announces Pooled Results From TRuE-AD1 And TRuE-AD2
evaluating Ruxolitinib Cream
10/26/2020 9:01:55 AM
Incyte Says Health Canada Has Accepted Its New Drug Submission For Pemigatinib For Cholangiocarcinoma Treatment
9/21/2020 7:31:36 AM
MacroGenics Says $15 Mln Milestone Triggered By Initiation Of Phase 3 Trial In NSCLC By Incyte
9/18/2020 7:45:49 AM
CHMP Recommends Approval Of Lilly's Baricitinib For Moderate To Severe Atopic Dermatitis In Adults
9/18/2020 6:03:16 AM
Incyte Announces Results From Phase 2 POD1UM-202 Trial Of Retifanlimab
9/14/2020 6:33:37 AM
Lilly, Incyte Announce Initial Data Emerging From Adaptive COVID-19 Treatment Trial